Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > AstraZeneca Trial Patient Dies

<< Previous

Bullboard Posts

Next >>

Comment by 294everon Oct 21, 2020 2:07pm

117 Views

Post# 31755952

RE:AstraZeneca Trial Patient Dies

It would be interesting to know wether the patient died of COVID or of an adverse reaction to the vaccine.

Either way very sad news that this happened to this individual. My heart goes out to their loved ones.

The need for safe therapeutics is becoming more apparent as the days go on. A giant heartfelt thanks should go to all the people who have risked their health and wellbeing to help us advance these necessary treatments for the good of humanity in this bloody awful time.

Best to all

<< Previous

Bullboard Posts

Next >>

Three stocks with strong income statements to buy right now